Literature DB >> 17496912

KSR and CNK: two scaffolds regulating RAS-mediated RAF activation.

A Clapéron1, M Therrien.   

Abstract

The RAS-RAF-MEK-extracellular-regulated kinase (RAS/ERK) pathway is a major intracellular route used by metazoan cells to channel to downstream targets a diverse array of signals, including those controlling cell proliferation and survival. Recent findings suggest that the pathway is assembled by specific scaffolding proteins that in turn regulate the efficiency, the location and/or the duration of signal transmission. Here, through the angle of studies conducted in Drosophila and C. elegans, we present two such proteins, the kinase suppressor of RAS (KSR) and connector enhancer of KSR (CNK) scaffolds, and highlight their implication in a novel mechanism regulating RAS-mediated RAF activation. Based on recent findings, we discuss the possibility that KSR, a RAF-like protein, does not solely act as a scaffold, but directly induces RAF catalytic function by a kinase-independent mechanism apparently shared by RAF-like proteins.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17496912     DOI: 10.1038/sj.onc.1210408

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  55 in total

Review 1.  Organization of the ENaC-regulatory machinery.

Authors:  Rama Soundararajan; Ming Lu; David Pearce
Journal:  Crit Rev Biochem Mol Biol       Date:  2012-04-16       Impact factor: 8.250

Review 2.  Mechanistic principles of RAF kinase signaling.

Authors:  Christian M Udell; Thanashan Rajakulendran; Frank Sicheri; Marc Therrien
Journal:  Cell Mol Life Sci       Date:  2010-09-06       Impact factor: 9.261

3.  Suppression of Ras/Mapk pathway signaling inhibits Myc-induced lymphomagenesis.

Authors:  M W Gramling; C M Eischen
Journal:  Cell Death Differ       Date:  2012-02-03       Impact factor: 15.828

4.  Shoc2-tranduced ERK1/2 motility signals--Novel insights from functional genomics.

Authors:  Myoungkun Jeoung; Eun Ryoung Jang; Jinpeng Liu; Chi Wang; Eric C Rouchka; Xiaohong Li; Emilia Galperin
Journal:  Cell Signal       Date:  2016-02-11       Impact factor: 4.315

5.  Dual Farnesyl and Geranylgeranyl Transferase Inhibitor Thwarts Mutant KRAS-Driven Patient-Derived Pancreatic Tumors.

Authors:  Aslamuzzaman Kazi; Shengyan Xiang; Hua Yang; Liwei Chen; Perry Kennedy; Muhammad Ayaz; Steven Fletcher; Christopher Cummings; Harshani R Lawrence; Francisca Beato; Ya'an Kang; Michael P Kim; Andrea Delitto; Patrick W Underwood; Jason B Fleming; Jose G Trevino; Andrew D Hamilton; Said M Sebti
Journal:  Clin Cancer Res       Date:  2019-06-21       Impact factor: 12.531

6.  IQGAP1 regulates ERK1/2 and AKT signalling in the heart and sustains functional remodelling upon pressure overload.

Authors:  Mauro Sbroggiò; Daniela Carnevale; Alessandro Bertero; Giuseppe Cifelli; Emanuele De Blasio; Giada Mascio; Emilio Hirsch; Wadie F Bahou; Emilia Turco; Lorenzo Silengo; Mara Brancaccio; Giuseppe Lembo; Guido Tarone
Journal:  Cardiovasc Res       Date:  2011-04-14       Impact factor: 10.787

7.  IMP modulates KSR1-dependent multivalent complex formation to specify ERK1/2 pathway activation and response thresholds.

Authors:  Chiyuan Chen; Robert E Lewis; Michael A White
Journal:  J Biol Chem       Date:  2008-03-10       Impact factor: 5.157

8.  The Caenorhabditis elegans ekl (enhancer of ksr-1 lethality) genes include putative components of a germline small RNA pathway.

Authors:  Christian E Rocheleau; Kevin Cullison; Kai Huang; Yelena Bernstein; Annina C Spilker; Meera V Sundaram
Journal:  Genetics       Date:  2008-02-03       Impact factor: 4.562

Review 9.  Scaffold proteins and immune-cell signalling.

Authors:  Andrey S Shaw; Erin L Filbert
Journal:  Nat Rev Immunol       Date:  2009-01       Impact factor: 53.106

10.  Calcineurin inhibitors activate the proto-oncogene Ras and promote protumorigenic signals in renal cancer cells.

Authors:  Dipak Datta; Alan G Contreras; Aninda Basu; Olivier Dormond; Evelyn Flynn; David M Briscoe; Soumitro Pal
Journal:  Cancer Res       Date:  2009-11-10       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.